以上より、がん浸潤・転移の動力源として見出されたMT1-MMPは、細胞膜上で様々な膜蛋白質と相互作用することで、がんの多様な悪性形質の獲得に寄与すること、MT1-MMPのプロセシングを受けた膜蛋白質が新たな細胞機能を獲得し、がん治療や診断の新たな標的となることを強く示唆しています。現在、これまでの基礎研究の知見を元にしたトランスレーショナルリサーチを進め、MT1-MMPとその関連分子を標的としたシーズの臨床有用性(Proof of Concept:POC)を得ることで、独創的ながん治療・診断法を社会に向けて発信してゆきます。
研究成果
1.Nagano M, Hoshino D, Toshima J, Seiki M, Koshikawa N. NH2-terminal fragment of ZF21 protein suppresses tumor invasion via inhibiting the interaction of ZF21 with FAK: Cancer Science, in press.
2.Suzuki M, Muroi A, Nojima M, Numata A, Takasaki H, Sakai R, Yokose T, Miyagi Y, Koshikawa N. Utility of a Reverse Phase Protein Array to Evaluate Multiple Biomarkers in Diffuse Large B-Cell Lymphoma: Proteomics Clin Appl. 2020 Jan;14(1):e1900091. doi: 10.1002/prca.201900091.
3.Yasuda H, Nakagawa M, Kiyokawa H, Yoshida E, Yoshimura T, Koshikawa N, Itoh F, Seiki M. Unique Biological Activity and Potential Role of Monomeric Laminin-γ2 as a Novel Biomarker for Hepatocellular Carcinoma: A Review. Int J Mol Sci. 2019 Jan 8;20(1):226. doi: 10.3390/ijms20010226.
4.Takahashi Y, Hamasaki M, Aoki M, Koga K, Koshikawa N, Miyamoto S, Nabeshima K. Activated EphA2 Processing by MT1-MMP Is Involved in Malignant Transformation of Ovarian Tumours In Vivo. Anticancer Res. 2018 Jul;38(7):4257-4266. doi: 10.21873/anticanres.
5.Kikuchi K, Kozuka-Hata H, Oyama M, Seiki M, Koshikawa N. Identification of Proteolytic Cleavage Sites of EphA2 by Membrane Type 1 Matrix Metalloproteinase on the Surface of Cancer Cells. Methods Mol Biol. 2018;1731:29-37. doi:10.1007/978-1-4939-7595-2_3.
6.Koshikawa N, Minegishi T, Kiyokawa H, Seiki M. Specific detection of soluble EphA2 fragments in blood as a new biomarker for pancreatic cancer. Cell Death Dis. 2017 Oct 26;8(10):e3134. doi: 10.1038/cddis.2017.545.
7.Nakagawa M, Karashima T, Kamada M, Yoshida E, Yoshimura T, Nojima M, Inoue K, Shuin T, Seiki M, Koshikawa N. Development of a fully automated chemiluminescence immunoassay for urine monomeric laminin-γ2 as a promising diagnostic tool of non-muscle invasive bladder cancer. Biomarker Res. 2017 Oct 13;5:29. doi: 10.1186/s40364-017-0109-4.
8.Suzuki T, Minerva D, Nishiyama K, Koshikawa N Chaplain MAJ. Study on the tumor-induced angiogenesis using mathematical models. Cancer Sci. 2018 Jan;109(1):15-23. doi: 10.1111/cas.13395.
9.Kiyokawa H, Yasuda H, Oikawa R, Okuse C, Matsumoto N, Ikeda H, Watanabe T, Yamamoto H, Itoh F, Otsubo T, Yoshimura T, Yoshida E, Nakagawa M, Koshikawa N, Seiki M. Serum monomeric laminin-γ2 as a novel biomarker for hepatocellular carcinoma. Cancer Sci. 2017 Jul;108(7):1432-1439. doi: 10.1111/cas.13261.
10.Tatsukawa R, Koga K, Aoki M, Koshikawa N, Imafuku S, Nakayama J, Nabeshima K. Immunohistochemical demonstration of EphA2 processing by MT1-MMP in invasive cutaneous squamous cell carcinoma. Virchows Arch. 2016 Jul;469(1):25-34. doi: 10.1007/s00428-016-1934-9.
11.Kamada M, Koshikawa N, Minegishi T, Kawada C, Karashima T, Shuin T, Seiki M. Urinary laminin-γ2 is a novel biomarker of non-muscle invasive urothelial carcinoma. Cancer Sci. 2015 Dec;106(12):1730-7. doi: 10.1111/cas.12832.
12.Koshikawa N, Hoshino D, Taniguchi H, Minegishi T, Tomari T, Nam SO, Aoki M, Sueta T, Nakagawa T, Miyamoto S, Nabeshima K, Weaver AM, Seiki M. Proteolysis of EphA2 Converts It from a Tumor Suppressor to an Oncoprotein. Cancer Res. 2015 Aug 15;75(16):3327-39. doi: 10.1158/0008-5472.CAN-14-2798.
13.Kikuchi K, Noguchi A, Kasajima R, Miyagi Y, Hoshino D, Koshikawa N, Kubota A, Yokose T, Takano Y. Association of SIRT1 and tumor suppressor gene TAp63 expression in head and neck squamous cell carcinoma. Tumour Biol. 2015 Sep;36(10):7865-72. doi: 10.1007/s13277-015-3515-y.
14.Ito-Kureha T, Koshikawa N, Yamamoto M, Semba K, Yamaguchi N, Yamamoto T, Seiki M, Inoue J. Tropomodulin 1 expression driven by NF-κB enhances breast cancer growth. Cancer Res. 2015 Jan 1;75(1):62-72. doi: 10.1158/0008-5472.
15.Koshikawa N, Mizushima H, Minegishi T, Eguchi F, Yotsumoto F, Nabeshima K, Miyamoto S, Mekada E, Seiki M. Proteolytic activation of heparin-binding EGF-like growth factor by membrane-type matrix metalloproteinase-1 in ovarian carcinoma cells. Cancer Sci. 2011 Jan;102(1):111-6. doi:10.1111/j.1349-7006.
16.Koshikawa N, Mizushima H, Minegishi T, Iwamoto R, Mekada E, Seiki M. Membrane type 1-matrix metalloproteinase cleaves off the NH2-terminal portion of heparin-binding epidermal growth factor and converts it into a heparin-independent growth factor. Cancer Res. 2010 Jul 15;70(14):6093-103. doi:10.1158/0008-5472.CAN-10-0346.
17.Niiya D, Egawa N, Sakamoto T, Kikkawa Y, Shinkawa T, Isobe T, Koshikawa N, Seiki M. Identification and characterization of Lutheran blood group glycoprotein as a new substrate of membrane-type 1 matrix metalloproteinase 1 (MT1-MMP): a systemic whole cell analysis of MT1-MMP-associating proteins in A431 cells. J Biol Chem. 2009 Oct 2;284(40):27360-9. doi:10.1074/jbc.M109.029124.
18.Tomari T, Koshikawa N Uematsu T, Shinkawa T, Hoshino D, Egawa N, Isobe T,Seiki M. High throughput analysis of proteins associating with a proinvasive MT1-MMP in human malignant melanoma A375 cells. Cancer Sci. 2009 Jul;100(7):1284-90. doi: 10.1111/j.1349-7006.2009.01173.x.
19.Koshikawa N, Minegishi T, Nabeshima K, Seiki M. Development of a new tracking tool for the human monomeric laminin-gamma 2 chain in vitro and in vivo. Cancer Res. 2008 Jan 15;68(2):530-6. doi: 10.1158/0008-5472.CAN-07-5269.
20.Koshikawa N, Giannelli G, Cirulli V, Miyazaki K, Quaranta V. Role of cell surface metalloprotease MT1-MMP in epithelial cell migration over laminin-5. J Cell Biol. 2000 Feb 7;148(3):615-24. doi: 10.1083/jcb.148.3.615.
21.Koshikawa N, Moriyama K, Takamura H, Mizushima H, Nagashima Y, Yanoma S, Miyazaki K. Overexpression of laminin gamma2 chain monomer in invading gastric carcinoma cells. Cancer Res. 1999 Nov 1;59(21):5596-601. PMID: 10554040.